Lete-Cel Shows Promise in Treating Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Promising Results for Rare Sarcomas: New Treatment Shows Durable Responses
New York, NY – A groundbreaking clinical trial is offering hope to patients battling two rare and aggressive forms of sarcoma.substudy 2 of the phase 2 IGNYTE-ESO trial, focusing on letetresgene autoleucel (lete-cel), has shown encouraging results in treating synovial sarcoma (SyS) and myxoid/round cell liposarcoma (MRCLS).
“The overall response rate at the primary analysis was 42%…and importantly, the responses do seem to be durable,” said Dr. Sandra P. D’Angelo, a medical oncologist at Memorial Sloan Kettering Cancer Center, discussing the trial’s findings. “These results are actually quite compelling when we put them into the context of current standard approved options for patients with synovial sarcoma and myxoid/round cell liposarcoma.”
The trial, which is ongoing and international, enrolled 64 patients with advanced or metastatic SyS and MRCLS. Participants were either treatment-naive or had received prior treatment.The median age of participants was 46, reflecting the typical age range for these sarcoma subtypes, and 56% were male.Extraordinary Response rates and Durability
The interim analysis revealed an overall response rate (ORR) of 42% among evaluable patients. This included 6 complete responses and 21 partial responses. Notably, response rates were similar across both sarcoma subtypes, with 41% of SyS patients and 43% of MRCLS patients achieving a response.
Perhaps even more encouraging, the responses to lete-cel appeared to be durable. The median duration of response (DOR) for the entire cohort was 12.2 months. Patients with SyS experienced an even longer median DOR of 18.3 months, while those with MRCLS had a median DOR of 12.2 months. the median progression-free survival (PFS) was 5.3 months.
Hope for the Future
Dr. D’Angelo emphasized the significance of these findings, particularly in light of the limited treatment options currently available for SyS and MRCLS. The results of this substudy offer a glimmer of hope for patients facing these challenging diagnoses.Further research and analysis are ongoing, but the initial results of the IGNYTE-ESO trial suggest that lete-cel may represent a significant advancement in the treatment of these rare and aggressive sarcomas.
Durable Responses Seen in Rare Sarcomas Treated wiht Novel Therapy
New Saracoma Treatment Shows Promise
A new treatment for two rare and aggressive forms of sarcoma is showing encouraging results in a phase 2 clinical trial. Substudy 2 of teh IGNYTE-ESO trial, focusing on the drug letetresgene autoleucel (lete-cel), has demonstrated promising overall response rates and durable responses in patients with synovial sarcoma (SyS) and myxoid/round cell liposarcoma (MRCLS).
“The overall response rate at the primary analysis was 42%…and importantly, the responses do seem to be durable,” reported Dr. Sandra P. D’Angelo, a medical oncologist at Memorial Sloan Kettering Cancer Center.
The trial, which is ongoing and international, enrolled 64 patients with advanced or metastatic SyS and MRCLS. Both treatment-naive patients and those who had received prior treatment were included.
Important Response Rates and Durability
The interim analysis, which assessed responses in evaluable patients, revealed an overall response rate (ORR) of 42%. This included 6 complete responses and 21 partial responses. Response rates were consistent across both sarcoma subtypes, with 41% of SyS patients and 43% of MRCLS patients achieving a response.
Furthermore, the responses to lete-cel appear to be durable. The median duration of response (DOR) for the entire cohort was 12.2 months, with a median DOR of 18.3 months for SyS patients and 12.2 months for MRCLS patients. The median progression-free survival (PFS) was 5.3 months.
These findings are especially notable given the limited treatment options currently available for SyS and MRCLS.
Dr. D’Angelo highlighted the significance of the trial results, stating: “These results are actually quite compelling when we put them into the context of current standard approved options for patients with synovial sarcoma and myxoid/round cell liposarcoma.”
Further research and analysis are ongoing, but the early results of the IGNYTE-ESO trial suggest that lete-cel may represent a significant advancement in the treatment of these rare and aggressive sarcomas.